Rapid Tests Market by Product (Over-the-counter Rapid Test, Professional Rapid Test, and Others), Application (Infectious Disease, Cardiology, Oncology, Pregnancy, Infertility, Toxicology, Glucose Monitoring, and Others), and End User (Hospitals & Clinics

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,125	245 Pages	Allied Market Research	February, 2022	ALMR17117559

Best Price Guarantee
Price	from $4,125
Length	245 Pages
Publisher	Allied Market Research
Published Date	February, 2022
SKU	ALMR17117559

Rapid Tests Market by Product (Over-the-counter Rapid Test, Professional Rapid Test, and Others), Application (Infectious Disease, Cardiology, Oncology, Pregnancy, Infertility, Toxicology, Glucose Monitoring, and Others), and End User (Hospitals & Clinics, Home Care, Diagnostic Center, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

The global rapid tests market was valued at $33,329.15 million in 2020, and is projected to reach $97,606.33 million by 2030, registering a CAGR of 11.3% from 2021 to 2030.

Rapid tests are diagnostic assays designed for use where preliminary screening tests need to be conducted. These tests are easy, quick, and provide specific results; hence, are used in settings with limited resources. Rapid tests are incorporated in diagnosis of different diseases and health conditions such as HIV, influenza, malaria, cancer, pregnancy & fertility, and others.

The rapid tests market is expected to grow at a significant rate during the forecast period owing to increase in awareness regarding early diagnosis of disease, prevalence of infectious diseases, and need for low cost as well as accurate diagnostic testing. In addition, growth in personalized care and increased promotional activities by manufacturers encourage the usage of rapid tests, which further facilitate the growth of the market. However, stringent government regulations for the approval of rapid tests and recall of several products due to false results are expected to impede the market growth.

The rapid tests market is segmented based on product, application, end user, and region. Based on product, the market is bifurcated into over-the-counter (OTC) rapid test product and professional rapid test product. By application, the market is classified into infectious disease, cardiology, oncology, pregnancy & fertility, toxicology, glucose monitoring, and others. According to end user, it is segmented into hospital & clinic, diagnostic laboratory, home care, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the MRI system market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Product:

Over-the-counter (OTC) Rapid Test Products
Professional Rapid Test Products

By Application:

Infectious Disease
HPV
Hepatitis
Influenza
Malaria
HIV
Others
Cardiology
Oncology
Pregnancy & Fertility
Toxicology
Glucose Monitoring
Others

By End User

Hospitals & Clinics
Diagnostic Laboratories
Home Care
Others

BY Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

Akers Biosciences, Inc.
Alere Inc. (Abbott Laboratories)
Becton, Dickinson and Company
Bio-rad Laboratories, Inc.
Cepheid, Inc.
Hologic, Inc.
Meridian Bioscience, Inc.
OraSure Technologies, Inc.
Quidel Corporation
Roche Diagnostics

CHAPTER 1:INTRODUCTION: 1.1.Report Description; 1.2.Key Market Segments; 1.3.Key Benefits; 1.4.Research Methodology; 1.4.1. Primary Research; 1.4.2. Secondary Research; 1.4.3. Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE: 3.1.Market Definition and Scope; 3.2.Key Findings; 3.2.1. Top Investment Pockets; 3.2.2. Top Winning Strategies; 3.3.Porter's Five Forces Analysis; 3.3.1. Bargaining Power of Suppliers; 3.3.2. Threat of New Entrants; 3.3.3. Threat of Substitutes; 3.3.4. Competitive Rivalry; 3.3.5. Bargaining Power among Buyers; 3.4.Market Share Analysis/Top Player Positioning; 3.4.1. Market Share Analysis/Top Player Positioning 2020; 3.5.Market Dynamics; 3.5.1. Drivers; 3.5.2. Restraints; 3.5.3. Opportunities; 3.6.COVID-19 Impact Analysis
CHAPTER 4:RAPID TESTS MARKET, BY PRODUCT: 4.1.Market Overview; 4.1.1Market Size and Forecast, By Product; 4.2. Over-the-counter (OTC) Rapid Test Products; 4.2.1. Key Market Trends, Growth Factors and Opportunities; 4.2.2. Market Size and Forecast, By Region; 4.2.3. Market Share Analysis, By Country; 4.3. Professional Rapid Test Products; 4.3.1. Key Market Trends, Growth Factors and Opportunities; 4.3.2. Market Size and Forecast, By Region; 4.3.3. Market Share Analysis, By Country
CHAPTER 5:RAPID TESTS MARKET, BY APPLICATION: 5.1.Market Overview; 5.1.1Market Size and Forecast, By Application; 5.2. Infectious Disease; 5.2.1. Market Size and Forecast, By Region; 5.2.2. Market Share Analysis, By Country; 5.2.3. HPV rapid tests; 5.2.4.1. Market Size and Forecast; 5.2.4. Hepatitis rapid tests; 5.2.5.1. Market Size and Forecast; 5.2.5. Influenza rapid tests; 5.2.6.1. Market Size and Forecast; 5.2.6. Malaria rapid tests; 5.2.7.1. Market Size and Forecast; 5.2.7. HIV rapid tests; 5.2.8.1. Market Size and Forecast; 5.2.8. Other infectious disease rapid tests; 5.2.9.1. Market Size and Forecast; 5.3. Cardiology; 5.3.1. Market Size and Forecast, By Region; 5.3.2. Market Share Analysis, By Country; 5.4. Oncology; 5.4.1. Market Size and Forecast, By Region; 5.4.2. Market Share Analysis, By Country; 5.5. Pregnancy & Fertility; 5.5.1. Market Size and Forecast, By Region; 5.5.2. Market Share Analysis, By Country; 5.6. Toxicology; 5.6.1. Market Size and Forecast, By Region; 5.6.2. Market Share Analysis, By Country; 5.7. Glucose Monitoring; 5.7.1. Market Size and Forecast, By Region; 5.7.2. Market Share Analysis, By Country; 5.8. Other Applications; 5.8.1. Market Size and Forecast, By Region; 5.8.2. Market Share Analysis, By Country
CHAPTER 6:RAPID TESTS MARKET, BY END USER: 6.1.Market Overview; 6.1.1Market Size and Forecast, By End User; 6.2. Hospitals & Clinics; 6.2.1. Market Size and Forecast, By Region; 6.2.2. Market Share Analysis, By Country; 6.3. Diagnostic Laboratories; 6.3.1. Market Size and Forecast, By Region; 6.3.2. Market Share Analysis, By Country; 6.4. Home Care; 6.4.1. Market Size and Forecast, By Region; 6.4.2. Market Share Analysis, By Country; 6.5. Others; 6.5.1. Market Size and Forecast, By Region; 6.5.2. Market Share Analysis, By Country
CHAPTER 7:RAPID TESTS MARKET, BY REGION: 7.1.Market Overview; 7.1.1Market Size and Forecast, By Region; 7.2.North America; 7.2.1. Key Market Trends and Opportunities; 7.2.2. Market Size and Forecast, By Product; 7.2.3. Market Size and Forecast, By Application; 7.2.4. Market Size and Forecast, By End User; 7.2.5. Market Size and Forecast, By Country; 7.2.6. United States Rapid Tests Market; 7.2.6.1. Market Size and Forecast, By Product; 7.2.6.2. Market Size and Forecast, By Application; 7.2.6.3. Market Size and Forecast, By End User; 7.2.7. Canada Rapid Tests Market; 7.2.7.1. Market Size and Forecast, By Product; 7.2.7.2. Market Size and Forecast, By Application; 7.2.7.3. Market Size and Forecast, By End User; 7.2.8. Mexico Rapid Tests Market; 7.2.8.1. Market Size and Forecast, By Product; 7.2.8.2. Market Size and Forecast, By Application; 7.2.8.3. Market Size and Forecast, By End User; 7.3.Europe; 7.3.1. Key Market Trends and Opportunities; 7.3.2. Market Size and Forecast, By Product; 7.3.3. Market Size and Forecast, By Application; 7.3.4. Market Size and Forecast, By End User; 7.3.5. Market Size and Forecast, By Country; 7.3.6. Germany Rapid Tests Market; 7.3.6.1. Market Size and Forecast, By Product; 7.3.6.2. Market Size and Forecast, By Application; 7.3.6.3. Market Size and Forecast, By End User; 7.3.7. France Rapid Tests Market; 7.3.7.1. Market Size and Forecast, By Product; 7.3.7.2. Market Size and Forecast, By Application; 7.3.7.3. Market Size and Forecast, By End User; 7.3.8. Uk Rapid Tests Market; 7.3.8.1. Market Size and Forecast, By Product; 7.3.8.2. Market Size and Forecast, By Application; 7.3.8.3. Market Size and Forecast, By End User; 7.3.9. Italy Rapid Tests Market; 7.3.9.1. Market Size and Forecast, By Product; 7.3.9.2. Market Size and Forecast, By Application; 7.3.9.3. Market Size and Forecast, By End User; 7.3.10. Spain Rapid Tests Market; 7.3.10.1. Market Size and Forecast, By Product; 7.3.10.2. Market Size and Forecast, By Application; 7.3.10.3. Market Size and Forecast, By End User; 7.3.11. Rest Of Europe Rapid Tests Market; 7.3.11.1. Market Size and Forecast, By Product; 7.3.11.2. Market Size and Forecast, By Application; 7.3.11.3. Market Size and Forecast, By End User; 7.4.Asia-Pacific; 7.4.1. Key Market Trends and Opportunities; 7.4.2. Market Size and Forecast, By Product; 7.4.3. Market Size and Forecast, By Application; 7.4.4. Market Size and Forecast, By End User; 7.4.5. Market Size and Forecast, By Country; 7.4.6. Japan Rapid Tests Market; 7.4.6.1. Market Size and Forecast, By Product; 7.4.6.2. Market Size and Forecast, By Application; 7.4.6.3. Market Size and Forecast, By End User; 7.4.7. China Rapid Tests Market; 7.4.7.1. Market Size and Forecast, By Product; 7.4.7.2. Market Size and Forecast, By Application; 7.4.7.3. Market Size and Forecast, By End User; 7.4.8. India Rapid Tests Market; 7.4.8.1. Market Size and Forecast, By Product; 7.4.8.2. Market Size and Forecast, By Application; 7.4.8.3. Market Size and Forecast, By End User; 7.4.9. Australia Rapid Tests Market; 7.4.9.1. Market Size and Forecast, By Product; 7.4.9.2. Market Size and Forecast, By Application; 7.4.9.3. Market Size and Forecast, By End User; 7.4.10. South Korea Rapid Tests Market; 7.4.10.1. Market Size and Forecast, By Product; 7.4.10.2. Market Size and Forecast, By Application; 7.4.10.3. Market Size and Forecast, By End User; 7.4.11. Rest Of Asia-pacific Rapid Tests Market; 7.4.11.1. Market Size and Forecast, By Product; 7.4.11.2. Market Size and Forecast, By Application; 7.4.11.3. Market Size and Forecast, By End User; 7.5.LAMEA; 7.5.1. Key Market Trends and Opportunities; 7.5.2. Market Size and Forecast, By Product; 7.5.3. Market Size and Forecast, By Application; 7.5.4. Market Size and Forecast, By End User; 7.5.5. Market Size and Forecast, By Country; 7.5.6. Brazil Rapid Tests Market; 7.5.6.1. Market Size and Forecast, By Product; 7.5.6.2. Market Size and Forecast, By Application; 7.5.6.3. Market Size and Forecast, By End User; 7.5.7. South Africa, Rapid Tests Market; 7.5.7.1. Market Size and Forecast, By Product; 7.5.7.2. Market Size and Forecast, By Application; 7.5.7.3. Market Size and Forecast, By End User; 7.5.8. Saudi Arabia Rapid Tests Market; 7.5.8.1. Market Size and Forecast, By Product; 7.5.8.2. Market Size and Forecast, By Application; 7.5.8.3. Market Size and Forecast, By End User; 7.5.9. Rest of LAMEA Rapid Tests Market; 7.5.9.1. Market Size and Forecast, By Product; 7.5.9.2. Market Size and Forecast, By Application; 7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8:COMPANY PROFILES: 8.1. Akers Biosciences, Inc.; 8.1.1.Company Overview; 8.1.2.Key Executives; 8.1.3.Company snapshot; 8.1.4.Operating business segments; 8.1.5.Product portfolio; 8.1.6.Business Performance; 8.1.7.Key Strategic Moves and Developments; 8.2. Abbott Laboratories (Alere Inc.); 8.2.1.Company Overview; 8.2.2.Key Executives; 8.2.3.Company snapshot; 8.2.4.Operating business segments; 8.2.5.Product portfolio; 8.2.6.Business Performance; 8.2.7.Key Strategic Moves and Developments; 8.3. Becton, Dickinson And Company; 8.3.1.Company Overview; 8.3.2.Key Executives; 8.3.3.Company snapshot; 8.3.4.Operating business segments; 8.3.5.Product portfolio; 8.3.6.Business Performance; 8.3.7.Key Strategic Moves and Developments; 8.4. Bio-Rad Laboratories, Inc.; 8.4.1.Company Overview; 8.4.2.Key Executives; 8.4.3.Company snapshot; 8.4.4.Operating business segments; 8.4.5.Product portfolio; 8.4.6.Business Performance; 8.4.7.Key Strategic Moves and Developments; 8.5. Danaher Corporation (Cepheid, Inc.); 8.5.1.Company Overview; 8.5.2.Key Executives; 8.5.3.Company snapshot; 8.5.4.Operating business segments; 8.5.5.Product portfolio; 8.5.6.Business Performance; 8.5.7.Key Strategic Moves and Developments; 8.6. Hologic, Inc.; 8.6.1.Company Overview; 8.6.2.Key Executives; 8.6.3.Company snapshot; 8.6.4.Operating business segments; 8.6.5.Product portfolio; 8.6.6.Business Performance; 8.6.7.Key Strategic Moves and Developments; 8.7. Meridian Bioscience, Inc.; 8.7.1.Company Overview; 8.7.2.Key Executives; 8.7.3.Company snapshot; 8.7.4.Operating business segments; 8.7.5.Product portfolio; 8.7.6.Business Performance; 8.7.7.Key Strategic Moves and Developments; 8.8. OraSure Technologies, Inc.; 8.8.1.Company Overview; 8.8.2.Key Executives; 8.8.3.Company snapshot; 8.8.4.Operating business segments; 8.8.5.Product portfolio; 8.8.6.Business Performance; 8.8.7.Key Strategic Moves and Developments; 8.9. Quidel Corporation; 8.9.1.Company Overview; 8.9.2.Key Executives; 8.9.3.Company snapshot; 8.9.4.Operating business segments; 8.9.5.Product portfolio; 8.9.6.Business Performance; 8.9.7.Key Strategic Moves and Developments; 8.10. F. Hoffmann-La Roche AG (Roche Diagnostics); 8.10.1.Company Overview; 8.10.2.Key Executives; 8.10.3.Company snapshot; 8.10.4.Operating business segments; 8.10.5.Product portfolio; 8.10.6.Business Performance; 8.10.7.Key Strategic Moves and Developments
LIST OF TABLES: TABLE 1. GLOBAL RAPID TESTS MARKET, BY PRODUCT, 2020-2030 ($MILLION); TABLE 2. GLOBAL RAPID TESTS MARKET FOR OVER-THE-COUNTER (OTC) RAPID TEST PRODUCTS, BY REGION, 2020-2030 ($MILLION); TABLE 3. GLOBAL RAPID TESTS MARKET FOR PROFESSIONAL RAPID TEST PRODUCTS, BY REGION, 2020-2030 ($MILLION); TABLE 4. GLOBAL RAPID TESTS MARKET, BY APPLICATION, 2020-2030 ($MILLION); TABLE 5. GLOBAL RAPID TESTS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2020-2030 ($MILLION); TABLE 6. GLOBAL RAPID TESTS MARKET FOR CARDIOLOGY, BY REGION, 2020-2030 ($MILLION); TABLE 7. GLOBAL RAPID TESTS MARKET FOR ONCOLOGY, BY REGION, 2020-2030 ($MILLION); TABLE 8. GLOBAL RAPID TESTS MARKET FOR PREGNANCY & FERTILITY, BY REGION, 2020-2030 ($MILLION); TABLE 9. GLOBAL RAPID TESTS MARKET FOR TOXICOLOGY, BY REGION, 2020-2030 ($MILLION); TABLE 10. GLOBAL RAPID TESTS MARKET FOR GLUCOSE MONITORING, BY REGION, 2020-2030 ($MILLION); TABLE 11. GLOBAL RAPID TESTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2030 ($MILLION); TABLE 12. GLOBAL RAPID TESTS MARKET, BY END USER, 2020-2030 ($MILLION); TABLE 13. GLOBAL RAPID TESTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2030 ($MILLION); TABLE 14. GLOBAL RAPID TESTS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2030 ($MILLION); TABLE 15. GLOBAL RAPID TESTS MARKET FOR HOME CARE, BY REGION, 2020-2030 ($MILLION); TABLE 16. GLOBAL RAPID TESTS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION); TABLE 17. GLOBAL RAPID TESTS MARKET, BY REGION, 2020-2030 ($MILLION); TABLE 18. NORTH AMERICA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 19. NORTH AMERICA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 20. NORTH AMERICA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 21. UNITED STATES RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 22. UNITED STATES RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 23. UNITED STATES RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 24. CANADA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 25. CANADA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 26. CANADA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 27. MEXICO RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 28. MEXICO RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 29. MEXICO RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 30. EUROPE RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 31. EUROPE RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 32. EUROPE RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 33. GERMANY RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 34. GERMANY RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 35. GERMANY RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 36. FRANCE RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 37. FRANCE RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 38. FRANCE RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 39. UK RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 40. UK RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 41. UK RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 42. ITALY RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 43. ITALY RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 44. ITALY RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 45. SPAIN RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 46. SPAIN RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 47. SPAIN RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 48. REST OF EUROPE RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 49. REST OF EUROPE RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 50. REST OF EUROPE RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 51. ASIA-PACIFIC RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 52. ASIA-PACIFIC RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 53. ASIA-PACIFIC RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 54. JAPAN RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 55. JAPAN RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 56. JAPAN RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 57. CHINA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 58. CHINA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 59. CHINA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 60. INDIA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 61. INDIA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 62. INDIA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 63. AUSTRALIA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 64. AUSTRALIA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 65. AUSTRALIA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 66. SOUTH KOREA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 67. SOUTH KOREA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 68. SOUTH KOREA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 69. REST OF ASIA-PACIFIC RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 70. REST OF ASIA-PACIFIC RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 71. REST OF ASIA-PACIFIC RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 72. LAMEA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 73. LAMEA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 74. LAMEA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 75. BRAZIL RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 76. BRAZIL RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 77. BRAZIL RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 78. SOUTH AFRICA, RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 79. SOUTH AFRICA, RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 80. SOUTH AFRICA, RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 81. SAUDI ARABIA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 82. SAUDI ARABIA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 83. SAUDI ARABIA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 84. REST OF LAMEA RAPID TESTS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 85. REST OF LAMEA RAPID TESTS, BY APPLICATION, 2020-2030 ($MILLION); TABLE 86. REST OF LAMEA RAPID TESTS, BY END USER, 2020-2030 ($MILLION); TABLE 87. AKERS BIOSCIENCES, INC.: KEY EXECUTIVES; TABLE 88. AKERS BIOSCIENCES, INC.: COMPANY SNAPSHOT; TABLE 89. AKERS BIOSCIENCES, INC.: OPERATING SEGMENTS; TABLE 90. AKERS BIOSCIENCES, INC.: PRODUCT PORTFOLIO; TABLE 91. AKERS BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 92. ABBOTT LABORATORIES (ALERE INC.): KEY EXECUTIVES; TABLE 93. ABBOTT LABORATORIES (ALERE INC.): COMPANY SNAPSHOT; TABLE 94. ABBOTT LABORATORIES (ALERE INC.): OPERATING SEGMENTS; TABLE 95. ABBOTT LABORATORIES (ALERE INC.): PRODUCT PORTFOLIO; TABLE 96. ABBOTT LABORATORIES (ALERE INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 97. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES; TABLE 98. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT; TABLE 99. BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS; TABLE 100. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO; TABLE 101. BECTON, DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 102. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES; TABLE 103. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT; TABLE 104. BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS; TABLE 105. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO; TABLE 106. BIO-RAD LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 107. DANAHER CORPORATION (CEPHEID, INC.): KEY EXECUTIVES; TABLE 108. DANAHER CORPORATION (CEPHEID, INC.): COMPANY SNAPSHOT; TABLE 109. DANAHER CORPORATION (CEPHEID, INC.): OPERATING SEGMENTS; TABLE 110. DANAHER CORPORATION (CEPHEID, INC.): PRODUCT PORTFOLIO; TABLE 111. DANAHER CORPORATION (CEPHEID, INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 112. HOLOGIC, INC.: KEY EXECUTIVES; TABLE 113. HOLOGIC, INC.: COMPANY SNAPSHOT; TABLE 114. HOLOGIC, INC.: OPERATING SEGMENTS; TABLE 115. HOLOGIC, INC.: PRODUCT PORTFOLIO; TABLE 116. HOLOGIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 117. MERIDIAN BIOSCIENCE, INC.: KEY EXECUTIVES; TABLE 118. MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT; TABLE 119. MERIDIAN BIOSCIENCE, INC.: OPERATING SEGMENTS; TABLE 120. MERIDIAN BIOSCIENCE, INC.: PRODUCT PORTFOLIO; TABLE 121. MERIDIAN BIOSCIENCE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 122. ORASURE TECHNOLOGIES, INC.: KEY EXECUTIVES; TABLE 123. ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT; TABLE 124. ORASURE TECHNOLOGIES, INC.: OPERATING SEGMENTS; TABLE 125. ORASURE TECHNOLOGIES, INC.: PRODUCT PORTFOLIO; TABLE 126. ORASURE TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 127. QUIDEL CORPORATION: KEY EXECUTIVES; TABLE 128. QUIDEL CORPORATION: COMPANY SNAPSHOT; TABLE 129. QUIDEL CORPORATION: OPERATING SEGMENTS; TABLE 130. QUIDEL CORPORATION: PRODUCT PORTFOLIO; TABLE 131. QUIDEL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 132. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): KEY EXECUTIVES; TABLE 133. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): COMPANY SNAPSHOT; TABLE 134. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): OPERATING SEGMENTS; TABLE 135. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): PRODUCT PORTFOLIO; TABLE 136. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES: FIGURE 1. GLOBAL RAPID TESTS MARKET SEGMENTATION; FIGURE 2. GLOBAL RAPID TESTS MARKET; FIGURE 3. SEGMENTATION RAPID TESTS MARKET; FIGURE 4. TOP INVESTMENT POCKET IN RAPID TESTS MARKET; FIGURE 5. TOP WINNING STRATEGIES, 2019-2021*; FIGURE 6. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%); FIGURE 7. TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*; FIGURE 8. MODERATE BARGAINING POWER OF BUYERS; FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 10. MODERATE THREAT OF NEW ENTRANTS; FIGURE 11. LOW THREAT OF SUBSTITUTION; FIGURE 12. HIGH COMPETITIVE RIVALRY; FIGURE 13. TOP PLAYER POSITIONING, 2020; FIGURE 14. MARKET SHARE ANALYSIS, 2020; FIGURE 15. RESTRAINTS AND DRIVERS: RAPID TESTS MARKET; FIGURE 16. RAPID TESTS MARKET SEGMENTATION, BY PRODUCT; FIGURE 17. RAPID TESTS MARKET FOR OVER-THE-COUNTER (OTC) RAPID TEST PRODUCTS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 18. RAPID TESTS MARKET FOR PROFESSIONAL RAPID TEST PRODUCTS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 19. RAPID TESTS MARKET SEGMENTATION, BY APPLICATION; FIGURE 20. RAPID TESTS MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 21. RAPID TESTS MARKET FOR CARDIOLOGY, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 22. RAPID TESTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 23. RAPID TESTS MARKET FOR PREGNANCY & FERTILITY, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 24. RAPID TESTS MARKET FOR TOXICOLOGY, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 25. RAPID TESTS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 26. RAPID TESTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 27. RAPID TESTS MARKET SEGMENTATION, BY END USER; FIGURE 28. RAPID TESTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 29. RAPID TESTS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 30. RAPID TESTS MARKET FOR HOME CARE, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 31. RAPID TESTS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 32. AKERS BIOSCIENCES, INC.: NET SALES, 2018-2020 ($MILLION); FIGURE 33. AKERS BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 34. AKERS BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 35. ABBOTT LABORATORIES (ALERE INC.): NET SALES, 2018-2020 ($MILLION); FIGURE 36. ABBOTT LABORATORIES (ALERE INC.): REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 37. ABBOTT LABORATORIES (ALERE INC.): REVENUE SHARE, BY REGION, 2020 (%); FIGURE 38. BECTON, DICKINSON AND COMPANY: NET SALES, 2018-2020 ($MILLION); FIGURE 39. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 40. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 41. BIO-RAD LABORATORIES, INC.: NET SALES, 2018-2020 ($MILLION); FIGURE 42. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 43. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 44. DANAHER CORPORATION (CEPHEID, INC.): NET SALES, 2018-2020 ($MILLION); FIGURE 45. DANAHER CORPORATION (CEPHEID, INC.): REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 46. DANAHER CORPORATION (CEPHEID, INC.): REVENUE SHARE, BY REGION, 2020 (%); FIGURE 47. HOLOGIC, INC.: NET SALES, 2018-2020 ($MILLION); FIGURE 48. HOLOGIC, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 49. HOLOGIC, INC.: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 50. MERIDIAN BIOSCIENCE, INC.: NET SALES, 2018-2020 ($MILLION); FIGURE 51. MERIDIAN BIOSCIENCE, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 52. MERIDIAN BIOSCIENCE, INC.: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 53. ORASURE TECHNOLOGIES, INC.: NET SALES, 2018-2020 ($MILLION); FIGURE 54. ORASURE TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 55. ORASURE TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 56. QUIDEL CORPORATION: NET SALES, 2018-2020 ($MILLION); FIGURE 57. QUIDEL CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 58. QUIDEL CORPORATION: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 59. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): NET SALES, 2018-2020 ($MILLION); FIGURE 60. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 61. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS): REVENUE SHARE, BY REGION, 2020 (%)